© Reuters. FILE PHOTO: Former drug company executive Martin Shkreli exits U.S. District Court after being convicted of securities fraud, in the Brooklyn borough of New York City, U.S., August 4, 2017. REUTERS/Carlo Allegri
WASHINGTON (Reuters) – A U.S. court said on Friday that Martin Shkreli, who famously raised the price of Daraprim, would be ordered to pay $64.6 million and would be barred for life from the pharmaceutical industry.
The drug is used to treat toxoplasmosis, a parasitic infection that threatens people with weakened immune systems.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.